(19)
(11) EP 3 634 997 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.04.2025 Bulletin 2025/14

(45) Mention of the grant of the patent:
26.02.2025 Bulletin 2025/09

(21) Application number: 18729642.1

(22) Date of filing: 04.06.2018
(51) International Patent Classification (IPC): 
C07K 16/18(2006.01)
 C07K 16/24(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/18; C07K 16/244; C07K 2317/24; C07K 2317/31; C07K 2317/33; C07K 2317/60; C07K 2317/622; C07K 2317/92; C07K 2317/94
(86) International application number:
PCT/EP2018/064622
(87) International publication number:
WO 2018/224439 (13.12.2018 Gazette 2018/50)

(54)

ANTI-HSA ANTIBODIES

ANTI-HSA-ANTIKÖRPER

ANTICORPS ANTI HSA

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 05.06.2017 US 201762515293 P
10.10.2017 EP 17195783

(43) Date of publication of application:
15.04.2020 Bulletin 2020/16

(73) Proprietor: Numab Therapeutics AG
8810 Horgen (CH)

(72) Inventors:
  • GUNDE, Tea
    8005 Zurich (CH)
  • MEYER, Sebastian
    5445 Eggenwil (CH)
  • HESS, Christian
    8045 Zurich (CH)
  • BIERI, Tessa
    1110 Morges (CH)

(74) Representative: Wallinger Ricker Schlotter Tostmann 
Patent- und Rechtsanwälte mbB Zweibrückenstraße 5-7
80331 München
80331 München (DE)


(56) References cited: : 
WO-A1-2010/035012
WO-A1-2013/068571
WO-A1-2016/202457
WO-A1-2019/072869
WO-A2-2010/094722
 WO-A1-2011/036460
WO-A1-2014/206561
WO-A1-2019/072868
WO-A1-2019/072870
WO-A2-2010/094723
   
  • EMMA DAVÉ ET AL: "Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding", MABS, vol. 8, no. 7, 17 August 2016 (2016-08-17), US, pages 1319 - 1335, XP055428628, ISSN: 1942-0862, DOI: 10.1080/19420862.2016.1210747
  • CHRISTIAN SCHRÖTER ET AL: "A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display", MABS, vol. 7, no. 1, 18 December 2014 (2014-12-18), US, pages 138 - 151, XP055428679, ISSN: 1942-0862, DOI: 10.4161/19420862.2014.985993
  • TIMOTHY J. EGAN ET AL: "Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments", MABS, vol. 9, no. 1, 27 October 2016 (2016-10-27), US, pages 68 - 84, XP055467772, ISSN: 1942-0862, DOI: 10.1080/19420862.2016.1248012
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).